Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12188601 | 0.86 | GAA (0.49) | SPRKMT2AMGLLALDH1A1GAA | |
| SCHEMBL1811165 | 0.85 | CCKAR (0.40) | SPRPIM1 | |
| SCHEMBL1806244 | 0.85 | SCN9A (0.46) | SPRPIM1MGLL | |
| SCHEMBL1810294 | 0.81 | SCN9A (0.45) | SPRPIM1KDM4EKMT2AMGLL | |
| SCHEMBL12188743 | 0.79 | SCN9A (0.49) | GAA | |
| SCHEMBL3025410 | 0.75 | CACNA1B (0.60) | — | |
| SCHEMBL12100617 | 0.73 | HSD11B1 (0.41) | PIM1KDM4EKMT2AMGLL | |
| SCHEMBL1810159 | 0.72 | SCD5 (0.54) | PIM1KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL12188558 | 0.71 | PIM1 (0.47) | PIM1KDM4EKMT2A | |
| SCHEMBL19692848 | 0.71 | AKR1C3 (0.44) | SPRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | SPR 1986/4885PIM1 4238/4885KDM4E 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.